Literature DB >> 19654529

Characteristics of endophthalmitis in patients with the Boston keratoprosthesis.

Robert E Fintelmann1, Joseph I Maguire, Allen C Ho, Hall F Chew, Brandon D Ayres.   

Abstract

PURPOSE: To determine the characteristics of endophthalmitis in patients with the Boston keratoprosthesis.
METHODS: Retrospective chart review of 4 out of 35 patients who underwent implantation of the Boston keratoprosthesis on the Wills Eye Cornea service between 2001 and 2007 and developed infectious endophthalmitis.
RESULTS: All 4 patients had keratoprosthesis surgery due to previous corneal transplant failure. The incidence of endophthalmitis was 11.4%. All patients were on topical antibiotic prophylaxis with a fluoroquinolone and 1 of the 4 patients was also using vancomycin drops. All 4 patients underwent a tap and inject and were admitted for intensive intravenous and topical antibiotics for 3 to 7 days. Culture positive results were found in 3 of the 4 vitreous samples: 2 coagulase-negative Staphylococcus, and 1 Pseudomonas and Staphylococcus aureus. Minimum Inhibitory Concentration data showed high resistance to fourth-generation fluoroquinolone antibiotics in all isolates. All patients recovered significant vision, except 1 patient who developed fluctuating vision secondary to vitreoretinal traction bands, which developed secondary to the endophthalmitis.
CONCLUSION: Endophthalmitis can occur after Boston keratoprosthesis at a significant rate, even in low-risk patients on prophylactic antibiotic drops. Given our experience with these patients and vancomycin, we recommend its prophylactic use. The increasing resistance of gram-positive organisms to fluoroquinolones and the need for close patient follow-up to encourage adherence to preventive regimens are further supported in this report.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654529     DOI: 10.1097/ICO.0b013e31819b0385

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results.

Authors:  Christopher J Rudnisky; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Jared D Ament; Brian J Zerbe; Joseph B Ciolino
Journal:  Ophthalmology       Date:  2012-02-22       Impact factor: 12.079

Review 2.  Endophthalmitis in Boston keratoprosthesis: case series and review of literature.

Authors:  Jay Chhablani; Bhavik Panchal; Taraparasad Das; Avinash Pathegay; Swapna R Motukupally; Rajeev Reddy Pappuru; Sayan Basu; Virender Sangwan
Journal:  Int Ophthalmol       Date:  2014-09-03       Impact factor: 2.031

3.  Anatomical survival and visual prognosis of Boston type I keratoprosthesis in challenging cases.

Authors:  Maria Fideliz de la Paz; Josef Stoiber; Valeria de Rezende Couto Nascimento; Juan Alvarez de Toledo; Orang Seyeddain; Wolfgang Hitzl; Günther Grabner; Rafael I Barraquer; Ralph Michael
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-25       Impact factor: 3.117

4.  Erratum to: Endophthalmitis in Boston keratoprosthesis: case series and review of literature.

Authors:  Jay Chhablani; Bhavik Panchal; Taraparasad Das; Avinash Pathengay; Swapna R Motukupally; Rajeev Reddy Pappuru; Sayan Basu; Virender Sangwan
Journal:  Int Ophthalmol       Date:  2015-02       Impact factor: 2.031

5.  Presumed endophthalmitis following Boston keratoprosthesis treated with 25 gauge vitrectomy: a report of three cases.

Authors:  Ilias Georgalas; Anastasios J Kanelopoulos; Petros Petrou; Ioannis Ladas; Eustratios Gotzaridis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

6.  Surface epithelialization of the type I Boston keratoprosthesis front plate: immunohistochemical and high-definition optical coherence tomography characterization.

Authors:  Lee Kiang; Mark I Rosenblatt; Rachel Sartaj; Ana G Alzaga Fernandez; Szilard Kiss; Nathan M Radcliffe; Donald J D'Amico; Kimberly C Sippel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-28       Impact factor: 3.117

Review 7.  Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA.

Authors:  Derek Metcalfe; Omer Iqbal; James Chodosh; Charles S Bouchard; Hajirah N Saeed
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.